Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy and safety of tislelizumab combined with bevacizumab and
platinum-based pemetrexed in the treatment of naïve patients with advanced non-squamous
non-small cell lung cancer with sensitive EGFR mutations and high PD-L1 expression
Prospective, open-label, single-arm phase II clinical study